Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.73 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.73 |
| ▸ | PTGES | O14684 | 1/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.66 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.64 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10001094 | 0.93 | HDAC6 (0.73) | HSD17B2TAS2R31PTGESALOX5MEN1 | |
| SCHEMBL10001092 | 0.91 | HSD17B2 (0.67) | HSD17B2TAS2R31PTGESALOX5MEN1 | |
| SCHEMBL10001087 | 0.91 | CYP1B1 (0.70) | HSD17B2TAS2R31PTGESALOX5MEN1 | |
| SCHEMBL6239788 | 0.87 | HSD17B2 (0.82) | HSD17B2TAS2R31MEN1POLBMAPT | |
| SCHEMBL30335183 | 0.87 | HSD17B2 (0.82) | HSD17B2TAS2R31MEN1POLBMAPT | |
| SCHEMBL29906158 | 0.87 | HSD17B2 (0.82) | HSD17B2TAS2R31MEN1POLBMAPT | |
| SCHEMBL10001101 | 0.86 | HSD17B2 (0.70) | HSD17B2TAS2R31MEN1POLBMAPT | |
| SCHEMBL16769856 | 0.86 | PTGES (0.84) | HSD17B2TAS2R31PTGESALOX5MEN1 | |
| SCHEMBL29359086 | 0.86 | PTGES (0.84) | HSD17B2TAS2R31PTGESALOX5MEN1 | |
| SCHEMBL10001096 | 0.86 | FLT3 (0.72) | MEN1POLBMAPTKMT2ACYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | TAIPEI MEDICAL UNIVERSITY (TW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | HSD17B2 220/4885TAS2R31 4176/4885PTGES 2172/4885 |
| US-20120029066-A1 | USE OF FLAVONES FOR TREATING PSYCHIATRIC DISORDERS WITH SENSORIMOTOR GATING DEFICITS | HTR2C, GRIN2C, HTR5A | HSD17B2 2273/4885TAS2R31 899/4885PTGES 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.